New Amine Oxidase Inhibitors and Enzymes in Oxidative Stress-Related Pathologies
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 10277
Special Issue Editors
Interests: amineoxidases; polyamines analogues; metalloenzymes; structure–function relationship studies; redox balance and antioxidants
Special Issues, Collections and Topics in MDPI journals
Interests: drug discovery; MAO inhibitors; anticancer drugs; natural compounds
Interests: enzymes kinetics; post-translational modifications in proteins; antioxidants and redox
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleague,
Amine oxidases (AOs) are a heterogeneous group of enzymes that catalyze the oxidative deamination of biogenic and exogenous amines to generate biologically active reaction products, such as aldehydes, ammonia and hydrogen peroxide, which may in turn influence cells and tissues. In particular, an overproduction of aldehydes and hydrogen peroxide has been related to a condition of oxidative stress, which is known to play an essential role in the pathogenesis and progression of many diseases, from neurodegenerative to cardiovascular diseases and diabetes mellitus, in addition to being associated with an increased risk of tumorigenesis. Consequently, AOs are considered important pharmacological targets in various pathologies, and various types of AO inhibitors have been developed, some of which are currently used in clinical settings.
Among the FAD-containing AOs, monoamine oxidase (MAO) A and B are some of the earliest and most well-known pharmacological targets in neurological and neurodegenerative diseases (such as depression, Parkinson’s and Alzheimer’s diseases). In recent years, to face these emerging multifactorial diseases, novel pharmacological strategies are being studied along with the design of novel types of inhibitors able to simultaneously attack different targets involved in the same pathology (for example, dual inhibitors for MAO and acetylcholine–butyrylcholinesterase). Additionally, recent studies have highlighted how increased MAO activity (mainly of the MAO A isoform) is also involved in some age-related diseases, such cardiac aging, heart failure and cancer, renewing the interest in the physiopathological role of these enzymes and opening new pharmacological perspectives.
Other examples of FAD-containing enzymes are the polyamine oxidases, involved in the catabolism of polyamines, whose levels increase in proliferating cells and are involved in cancer development. For this reason, the recently discovered spermine oxidase, an inducible enzyme, represents a potential target in cancer for which the development of potent and selective inhibitors is necessary.
Among the various topaquinone/semicarbazide-sensitive amine oxidases (SSAOs), it is worth underline the intriguing role of human vascular adhesion protein-1 (VAP-1), a multifunctional enzyme with two domains: an amine oxidase activity and an adhesive domain. Its amine oxidase activity is able to regulate the adhesion and migration of some leukocytes to the inflammation site and to modulate the inflammation signaling pathways. VAP-1 expression is abundant in the vascular system, and because of its important role in vascular inflammation, it is a potential target for different systemic and cerebral diseases, including stroke and Alzheimer’s disease. Additionally, VAP-1 is highly expressed in adipocyte cell membranes, liver endothelial cells and smooth muscle, and a soluble form of VAP-1 is released in plasma in some oxidative-related diseases. The physiopathological role of VAP-1 in these tissues is not well clarified and understood.
Therefore, it seems extremely important to study, in depth, the cellular pathways linked to the different AOs both to understand their role in the various pathologies and, consequently, to develop more focused therapies. Additionally, the development of novel inhibitors and novel pharmacological strategies seem necessary, particularly for the multifactorial and oxidative stress-related pathologies involving AOs.
The aim of this Special Issue is to collate original research, clinical studies and review articles describing the current findings on the development of novel inhibitors of the different AOs in targeting various pathologies, and on novel correlations between amine oxidase activity and the various oxidative stress-related diseases.
We are particularly interested in articles that might significantly contribute to better understanding of the biochemical and molecular mechanisms underlying the pathological role of AOs; articles focusing on pharmacological strategies involving AOs are also welcome.
Specific topics of interest include but are not limited to the following:
- Novel inhibitors of AOs in relation to oxidative stress-related pathologies;
- New pharmacological approaches involving AOs as molecular targets;
- Novel physiological and pathological roles of spermine oxidase, MAOs, VAP-1 and other AOs (lysyl oxidase, LSD-1, diamine oxidase, ...)
- Relationships between oxidative stress and amine oxidase activity under healthy and disease conditions.
Dr. Maria Luisa di Paolo
Prof. Dr. Lisa Dalla Via
Prof. Dr. Antonella Roveri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- amine oxidases
- oxidative stress
- drug discover
- spermine oxidase
- oxidative stress-related diseases
- multifactorial pathologies
- polyamine derivatives
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.